Webinar: EXTERNAL INNOVATION: REPLENISHING THE R&D PIPELINE
Sponsored by: Thomson Reuters
Focused on:
Date: 17th October
Days old: 4494
Time: 3PM London / 4PM Paris / 10AM New York
Replenishing the R&D pipeline by identifying, evaluating, and accessing novel research opportunities
External pressures have led to sweeping changes in the way companies find new drugs. Eroding revenues, cost pressures and pipeline failures have made large pharmaceutical companies more risk-averse and dependent upon academia and small companies for sourcing innovation. Companies large and small have also experimented with new research models: pre-competitive collaboration, innovation networks, micropharmas, public-private partnerships, on-line exchanges, etc.
The result has been the emergence of a thriving market for innovation where participants transact a growing volume of assets and services. The impact on R&D has been profound. Executives have increasingly turned to novel, knowledge-based approaches to identifying early the innovations and innovators. The value chain has also become more fragmented. Companies have tended to specialize, focusing on the steps where they enjoy a comparative advantage and in- or out-sourcing the rest. This specialization has lowered costs, and led to further slashing of internal efforts and overhead.
This webinar will focus on how the pharmaceutical industry is more actively seeking to leverage external innovation through collaborations with academia, biotech, and research institutes. In particular, we will discuss the open innovation models we are seeing and the knowledge-based approaches to finding novel assets emerging across the industry.
Register to participate in one of the hottest topics in R&D today - understanding and navigating external innovation landscape to gain access to assets faster.
Presented by
Bernard Munos,
Founder, InnoThink
Bernard Munos is the founder of InnoThink, a consultancy that focuses on pharmaceutical innovation - specifically, where it comes from and how to get more of it. He previously served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research has been published in Nature and Science, and was recently profiled by Forbes magazine. This year, the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma today. Munos received his M.B.A. from Stanford University, and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He advises companies, publicly-funded research organizations, and disease foundations on how to become better innovators.
John Cole,
Business Solutions Director, Life Sciences Professional Services, Thomson Reuters
John Cole has over 13 years of experience in strategic consulting with European and Global pharmaceutical clients on engagements across R&D, Business Development, and Commercial. John’s work focuses on helping companies identify the best product opportunities (either in-house or external) and how to maximize the commercial success of these assets. His specialist areas of expertise include Business Development and Licensing Support, R&D performance improvement, R&D organizational / operating model design and the R&D to commercial interface. He has a track record of successful project delivery with a major focus on implementing change. Prior to joining Thomson Reuters, John was an industry director in Ernst & Young's Pharmaceuticals practice based in London. Before Ernst & Young, he was a Senior Manager in Accenture's Health and Life Sciences Group and a senior member of their business strategy consulting team.
Kiran Meekings,
Business Practice Consultant, Life Sciences Professional Services, Thomson Reuters
Dr. Kiran Meekings is a Consultant within the Thomson Reuters Life Sciences Consulting Team. With over 7 years experience in the life sciences sector, she has a broad background encompassing clinical and scientific research, pharmaceutical equity research, pharmaceutical market analysis and consulting. Kiran holds a first-class degree in Natural Sciences from Cambridge University and a PhD in Viral Mechanisms of Oncogenesis from Imperial College London. Following her academic studies, Kiran gained experience as an equity research analyst at Merrill Lynch and as a pharmaceutical market research analyst at Decision Resources. She is proficient in top-down and bottom-up forecasting methodologies and has specific expertise in producing oncology product forecasts.
Download Slides
Please login to download the slidesKey Learning Objectives
- Identify innovation assets through novel means (grants, tech transfer analysis)
- Evaluate KOLs and research groups to identify the best people to collaborate with, now and for the future
- Change the model for accessing external innovation e.g. open innovation models, risk-sharing models, consortia etc
Audience
- VPs of R&D
- Heads of external innovation
- Business development leaders
- Heads of therapy areas
- Heads of R&D knowledge management
- Leaders of academic tech transfer offices